Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net | 256,147 | 194,430 | 421,050 | 351,644 |
| Operating expenses: | ||||
| Cost of sales | 4,061 | 3,433 | 6,944 | 5,836 |
| Research and development | 53,890 | 60,471 | 120,155 | 121,206 |
| Selling, general and administrative | 156,896 | 103,851 | 302,252 | 194,511 |
| Total operating expenses | 214,847 | 167,755 | 429,351 | 321,553 |
| Income (loss) from operations | 41,300 | 26,675 | (8,301) | 30,091 |
| Interest and other income | 4,631 | 5,017 | 9,517 | 11,219 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's R&D?
- Corcept Therapeutics (CORT) reported R&D of $53.89M in Q2 2026.
- How has Corcept Therapeutics's R&D changed year-over-year?
- Corcept Therapeutics's R&D decreased by 10.9% year-over-year, from $60.47M to $53.89M.
- What is the long-term trend for Corcept Therapeutics's R&D?
- Over 4 years (2021 to 2025), Corcept Therapeutics's R&D has grown at a 22.3% compound annual growth rate (CAGR), from $113.86M to $254.91M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Corcept Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude